| This week's sponsor is TD2. | |  | |
Featured Story | | | Friday, June 9, 2017 Mathai Mammen, M.D., Ph.D., is leaving Merck after a little more than one year to take up a position at Johnson & Johnson. The Theravance Biopharma co-founder is set to take over from William Hait, M.D., Ph.D., as global head of R&D, freeing his predecessor to start a new role overseeing J&J’s prolific partnering operation. |
|
|
| This week's sponsor is Althea. | |  | |
Top Stories Friday, June 9, 2017 Lexicon Pharmaceuticals has posted upbeat data from another phase 3 trial of its Sanofi-partnered dual SGLT1 and SGLT2 inhibitor sotagliflozin. More patients in the treatment arm hit an established target for glycemic control than did in the control cohort, resulting in Lexicon chalking up its third phase 3 success for the diabetes tablet. Friday, June 9, 2017 GlaxoSmithKline, Dupont and Bristol-Myers Squibb veteran Douglas Manion, M.D., FRCP(C), has become the new CEO of Kleo Pharmaceuticals. Monday, June 5, 2017 As the technology landscape of clinical trials evolves, apps are engaging patients in new ways and in real time, thus becoming an integral part of the healthcare infrastructure. Friday, June 9, 2017 Zebra Medical Vision has received a CE mark for its medical image analysis technology. The system uses algorithms to uncover evidence of fatty liver, coronary artery calcium, emphysema and other indicators of disease in CT scans. Thursday, June 8, 2017 AUSTIN, Texas—The United States has a crisis on its hands when it comes to high drug prices, Harvard Pilgrim Health Care President and CEO Eric Schultz said Thursday at the AHIP Institute & Expo. But it's still important to support innovation, and that's where value-based contracts come in. Thursday, June 8, 2017 Welcome to the latest edition of our weekly EuroBiotech Report. We started the week with two big deals for European biopharmas and ended with a big data readout. Friday, June 9, 2017 Chinese firm Nanjing Legend Biotech reported 100% overall response rate for its CAR-T cell product from an ongoing trial, Chi-Med touted its VEGF inhibitor fruquintinib's low liver toxicity profile, and Eisai's Lenvima could challenge Bayer's stalwart Nexavar in liver cancer. Thursday, June 8, 2017 Perrigo CEO Hendrickson will retire after just over a year at the job, Johnson & Johnson poaches Merck executive Mammen to head pharma R&D, Alexion brings on Baxalta alum John Orloff, M.D., as R&D chief, Bayer expands its oncology team with two SVP appointments, plus more hirings, firings and retirings throughout the industry. | | | The NIH has launched a special fund out of its existing budget for early- and midcareer scientists to try to support younger researchers. NIH blog Merck, hedging its bets against Bristol-Myers Squibb and AstraZeneca, is striking up a Keytruda-CTLA4 combo trial. FiercePharma article | |
|
Resources Sponsored by Envigo Performing a sophisticated surgery to create a myocardial infarction model. Join us on June 7th at 11:00 AM EDT. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Sponsored By: HealthCore Gain critical insights into how to design and implement pragmatic trials and generate relevant, high-level real-world evidence. Learn when to conduct PTs, design considerations, ethical regulatory issues — and more. Sponsored By: Veeva Join this global webinar to learn a new approach for demonstrating medical affairs' impact with better metrics - beyond reach and frequency, enabling launch success and better engagement with strategic KOL insights, and increasing your organization's share of voice in the healthcare landscape. Presented By: Covance The ICH GCP E6 guideline has been revised to address the complexities associated with today’s clinical trials, and this concise white paper will help you understand the recent guideline changes. Learn how use of risk-based monitoring can help you comply with the guidelines and achieve efficiency in clinical trial design, implementation and reporting. Presented By: Covance The recent evolution of immunotherapies and their potential applications have greatly impacted patients’ options for effective oncology treatments. These advances have been powered in part by the use of biomarkers, companion diagnostics (CDx) and complementary diagnostics. Read the white paper. Sponsored By: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Sponsored By: DocuSign The patients who rely on your scientific leadership are expecting more. Sponsored By: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. |
|
